Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
December 16 2019 - 4:15PM
Dynavax Technologies Corporation (NASDAQ: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced that Ryan Spencer has been
appointed Chief Executive Officer and to the Board of
Directors. David Novack has been appointed President and Chief
Operating Officer, reporting to Mr. Spencer. These appointments are
effective December 16, 2019.
“Through a rigorous, comprehensive search
process, Ryan emerged as the right business leader to guide
Dynavax, given his strong command of our business and proven
ability to lead and drive commercial execution in a complex
operating environment,” commented Arnold L. Oronsky, Ph.D.,
Chairman of the Board of Directors. “Ryan’s expertise across
corporate strategy, finance, and commercialization, with a track
record of leadership, combined with David’s tremendous experience
in vaccine development and manufacturing, results in an executive
leadership team with the full complement of experience required to
drive the growth and success of Dynavax.”
Mr. Spencer, who joined Dynavax in
2006, has held roles of increasing responsibility, building from a
foundation in corporate finance to business strategy and investor
relations, and culminating in his role as Senior Vice President,
Commercial. Since May of 2019, Mr. Spencer has served as the
Company’s interim co-President, a role he shared with Mr.
Novack.
Mr. Novack joined Dynavax in 2013, and has
led the company’s technical operations, supply chain, and quality
teams through FDA approval, launch, and commercialization
of HEPLISAV-B. Mr. Novack has more than 30 years of relevant
industry experience, with more than 20 years of direct vaccine
industry experience. Prior to Dynavax, Mr. Novack was
at Novartis where he served in various roles, including
Global Head of Technical Operations and Supply Chain for
Diagnostics, and Global Head of Manufacturing Strategy for
Vaccines.
“I am honored to take on this role at a
transformational time for Dynavax as we continue to build on our
commercial success with HEPLISAV-B,” commented Ryan Spencer, Chief
Executive Officer. “It is a privilege to work with a fantastic team
and a product that, based on its proven clinical profile, has the
potential to become the standard-of-care, adult hepatitis B vaccine
in the U.S. Dynavax is well positioned to build a global vaccine
business that improves patients’ lives, starting with
HEPLISAV-B.”
About DynavaxDynavax is a
commercial stage biopharmaceutical company developing and
commercializing novel vaccines. The Company launched HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], its first
commercial product, in February 2018, following U.S. FDA approval
for prevention of infection caused by all known subtypes of
hepatitis B virus in adults age 18 years and older. For more
information, visit www.dynavax.com and follow the company on
LinkedIn.
Forward Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the potential for HEPLISAV-B to become the emerging
standard of care in preventing hepatitis B infection in adults and
the potential U.S market opportunity for HEPLISAV-B. These
forward-looking statements are based upon management’s current
expectations, are subject to known and unknown risks, and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events may differ
materially from those anticipated in such forward-looking
statements due to various risks and uncertainties inherent in our
business, including, without limitation, the risk that that
prescribers and other key decision-makers at potential purchasing
entities may not make the decision to switch to HEPLISAV-B; and the
timing and quantity of actual purchases; risks related to market
adoption and competing therapies; and risks related to whether
payors will cover and provide timely and adequate reimbursement for
HEPLISAV-B. These and other risks are described in the "Risk
Factors" section of our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019, as well as discussions of
potential risks, uncertainties and other important factors in our
other filings with the U.S. Securities and Exchange Commission. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.
Contacts:Nicole Arndt, Senior
Manager, Investor Relationsnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations
Advisory Solutionsderek.cole@IRadvisory.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024